| 1367 |
National Cancer Institute |
Html |
en |
Skin Cancer Screening (PDQ®)–Health Professional Version |
Expert-reviewed information summary about tests used to detect or screen for skin cancer. |
| commonly occurring cancer | 0.623357 |
| skin cancer | 0.936474 |
| pediatric melanoma | 0.671304 |
| SCREEN study population | 0.580579 |
| skin awareness | 0.580742 |
| melanoma incidence rates | 0.734128 |
| observed modest mortality | 0.599763 |
| squamous cell cancers | 0.595008 |
| average annual incidence | 0.632599 |
| reduces melanoma mortality. | 0.659883 |
| health outcomes | 0.587808 |
| American Cancer Society | 0.618195 |
| important methodological limitations | 0.577191 |
| skin biopsy rates | 0.677147 |
| direct evidence | 0.584321 |
| nearly one-half | 0.583908 |
| two-stage skin cancer | 0.6325 |
| Medicare fee-for-service data | 0.592604 |
| U.S. cancer registries | 0.618554 |
| skin cancer screening | 0.7411 |
| melanoma | 0.802792 |
| UV radiation | 0.57829 |
| skin cancer awareness | 0.703316 |
| total-body visual examination | 0.577539 |
| vertical growth phase | 0.58165 |
|
| melanoma mortality rates | 0.760008 |
| reportable cancer | 0.578136 |
| End Results Program | 0.589373 |
| internal control group | 0.578284 |
| Basal cell carcinoma | 0.600196 |
| United States | 0.662165 |
| population-based skin cancer | 0.635467 |
| prolonged horizontal growth | 0.582398 |
| yearly incidence increase | 0.63333 |
| nonmelanoma skin cancers | 0.683707 |
| skin cancer. | 0.5773 |
| National Cancer Institute | 0.614591 |
| total number | 0.59851 |
| horizontal growth phase | 0.661114 |
| U.S. incidence rates | 0.65648 |
| main types | 0.601467 |
| initial pilot phase | 0.579738 |
| local disease | 0.593927 |
| skin lesions | 0.583166 |
| individual’s skin | 0.577585 |
| fewer melanoma death | 0.654325 |
| nonmelanoma skin cancer | 0.723959 |
| clinical visual screening | 0.595993 |
| SCREEN study | 0.606378 |
|
CLICK HERE |
| 1434 |
National Cancer Institute |
Html |
en |
Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia. |
| CLL | 0.563454 |
| German CLL Study | 0.551069 |
| monoclonal B-cell lymphocytosis | 0.528403 |
| Engl J Med | 0.555252 |
| trial | 0.525679 |
| leukemia group | 0.552678 |
| M. Prolymphocytic leukemia | 0.545972 |
| Routine chronic administration | 0.534661 |
| lymphocytic leukemia patients | 0.591222 |
| Leukemia group B. | 0.542105 |
| CLL Study Group | 0.54078 |
| cyclophosphamide | 0.529502 |
| Byrd JC | 0.527428 |
| Keating MJ | 0.535835 |
| advanced chronic | 0.539233 |
| patients | 0.592663 |
| Lymphocytic Leukemia Study | 0.593872 |
| T-cell prolymphocytic leukemia | 0.546745 |
| refractory high-risk chronic | 0.534243 |
| refractory chronic | 0.528565 |
| Adult Leukemia Group | 0.542021 |
| Leuk Lymphoma | 0.531402 |
| Lymphocytic Leukemia section | 0.595648 |
| fludarabine | 0.547348 |
| alemtuzumab versus fludarabine | 0.527105 |
|
| untreated B chronic | 0.530625 |
| et al. | 0.648755 |
| treatment | 0.535273 |
| small lymphocytic lymphoma | 0.590269 |
| French Cooperative Group | 0.528743 |
| German Chronic Lymphocytic | 0.583925 |
| Relapsed Chronic Lymphocytic | 0.579501 |
| acute myeloid leukemia | 0.53754 |
| stem cell | 0.529413 |
| Leukemia Study Group | 0.55235 |
| rituximab | 0.530116 |
| fludarabine-refractory B-cell chronic | 0.53547 |
| CLL therapy | 0.52689 |
| chronic lymphoid leukemia | 0.573599 |
| CLL Study Group. | 0.526303 |
| Abstract | 0.627578 |
| therapy | 0.53011 |
| Clin Oncol | 0.713099 |
| hairy cell leukemia | 0.553353 |
| blood | 0.56117 |
| chronic lymphocytic leukemia | 0.965039 |
| chronic lymphocytic leukaemia | 0.705583 |
| previously untreated patients | 0.578343 |
| allogeneic stem cell | 0.525551 |
|
CLICK HERE |
| 1900 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de cuello uterino (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de cuello uterino. |
| siguientes procedimientos | 0.302623 |
| Estadios llB | 0.300134 |
| estadios lB1 | 0.300176 |
| estadios ia | 0.300186 |
| estadio ivb | 0.3015 |
| cuello uterino.El estadio | 0.301223 |
| estadio iva | 0.301104 |
| proteÃna llamada factor | 0.30017 |
| estadios iiia | 0.300186 |
| recto.El cáncer | 0.301048 |
| áreas anormales.ampliar examen | 0.300205 |
| Instituto Nacional | 0.300194 |
| Cervical Cancer | 0.300274 |
| Drugs Approved | 0.300299 |
| pared pélvica.El cáncer | 0.30107 |
| medicamento des | 0.300142 |
| prueba pap | 0.300163 |
| principal factor | 0.300454 |
| siguientes estadios | 0.300489 |
| estadio lA1 | 0.300374 |
| funcionar.El cáncer | 0.301061 |
| estadios iva | 0.300174 |
| prueba pap.ampliar | 0.300132 |
| pequeñas incisiones | 0.30013 |
| estadificación quirúrgica pretratamiento | 0.300689 |
|
| pequeña cantidad | 0.300319 |
| estadio ii | 0.301571 |
| estadio ia | 0.301549 |
| enlace drugs approved | 0.300178 |
| estadio ila | 0.30036 |
| realidad células | 0.300277 |
| estadio ia2 | 0.300842 |
| cm.El estadio lB | 0.300541 |
| estadios iia | 0.300188 |
| estadio iiia | 0.300822 |
| PDQ Tratamiento | 0.300222 |
| estadio iia | 0.300852 |
| estadios ib1 | 0.300186 |
| siguientes signos | 0.300145 |
| Physician Data Query | 0.300387 |
| Ampliar Cáncer | 0.30485 |
| siguientes causas | 0.300199 |
| lápiz mide | 0.300224 |
| estadio iii | 0.301447 |
| cuello uterino | 0.99838 |
| cono.La conización | 0.30013 |
| histerectomÃa abdominal | 0.300165 |
| estadio ib2 | 0.300835 |
| siguientes sumarios | 0.300269 |
|
CLICK HERE |
| 1914 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores del sistema nervioso central en adultos (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los tumores del sistema nervioso central en adultos. |
| radiocirugÃa estereotáctica | 0.512702 |
| Organización Mundial | 0.518554 |
| gliomas mixtos | 0.51602 |
| Brain Tumors | 0.505258 |
| siguientes procedimientos | 0.502302 |
| adultos jóvenes | 0.506123 |
| siguientes aspectos | 0.504348 |
| faja ajustadora | 0.507035 |
| Turcot tipos | 0.506804 |
| siguientes afecciones | 0.507417 |
| carcinomas embrionarios | 0.505469 |
| células normales.ampliar exploración | 0.504663 |
| siguientes tipos | 0.506796 |
| rayos x | 0.507888 |
| Neurofibromatosis tipos | 0.506813 |
| encéfalo benignos | 0.526234 |
| enlace drugs approved | 0.509464 |
| carcinoma nevoide | 0.505116 |
|
| tumores benignos | 0.543382 |
| aparato explorador | 0.50369 |
| médula espinal.Tumores | 0.528221 |
| PDQ Tratamiento | 0.597843 |
| alta potencia | 0.50285 |
| tumores cerebrales | 0.516865 |
| saco vitelino | 0.505401 |
| siguientes factores | 0.504592 |
| sistema nervioso central | 0.930279 |
| menor daño | 0.503236 |
| cuerpo.ampliar exploración | 0.504376 |
| encéfalo.ampliar craneotomÃa | 0.503787 |
| von hippel-lindau | 0.505069 |
| tumores embrionarios | 0.532834 |
| cáncer.ampliar radioterapia | 0.506826 |
| radioterapia externa 3D | 0.508073 |
| radiocirugÃa estereotáxica | 0.502266 |
|
CLICK HERE |
| 1997 |
National Cancer Institute |
Html |
es |
Tratamiento de los astrocitomas infantiles (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los astrocitomas infantiles. |
| high-grade astrocytoma | 0.444609 |
| BRAF mutation | 0.44863 |
| pontine gliomas | 0.513199 |
| brain tumors | 0.449797 |
| cerebellar astrocytomas | 0.465185 |
| astrocitomas pilocÃticos | 0.812488 |
| Cancer Res | 0.478751 |
| thalamic gliomas from | 0.475546 |
| neurofibromatosis tipo | 0.470126 |
| pilocytic astrocytoma | 0.928999 |
| Children's Oncology Group | 0.451226 |
| optic-hypothalamic gliomas | 0.471792 |
| central nervous system | 0.495263 |
| gliomas reveals key | 0.471536 |
| h3f3a k27m mutation | 0.438972 |
| Nat Genet | 0.454568 |
| pediatric gliomas | 0.555458 |
| astrocitomas difusos).Recién | 0.471123 |
| Glioma Treated with | 0.441082 |
| Acta Neuropathol | 0.692887 |
| Pediatric Pilocytic Astrocytomas | 0.43879 |
| mutación braf v600e | 0.473181 |
| Organización Mundial | 0.468352 |
| Salud Grado | 0.453036 |
| Metastatic Low-Grade Gliomas | 0.479197 |
|
| braf v600e mutation | 0.454684 |
| astrocitomas infantiles grupo | 0.489856 |
| vÃa óptica | 0.453436 |
| Neuro Oncol | 0.501948 |
| BRAF V600E | 0.638339 |
| low-grade glioma | 0.976552 |
| Pediatr Blood Cancer | 0.686119 |
| gliomas with braf | 0.498818 |
| low-grade astrocytomas | 0.452781 |
| fusión braf-kiaa1549 | 0.457715 |
| childhood low-grade glioma | 0.438409 |
| optic pathway glioma | 0.455238 |
| mutaciones braf v600e | 0.497547 |
| diffuse high-grade astrocytomas | 0.440868 |
| malignant gliomas arising | 0.476149 |
| Clin Oncol | 0.452652 |
| nervous system tumors | 0.44069 |
| sistema nervioso central | 0.547399 |
| gliomas identifies recurrent | 0.476033 |
| mutaciones braf | 0.520493 |
| mutaciones puntuales braf | 0.489841 |
| Saluda Tipo Grado | 0.458304 |
| presuntos gliomas | 0.491024 |
| Neuropathol Exp Neurol | 0.51285 |
|
CLICK HERE |
| 2005 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores de estroma gastrointestinal (PDQ®)–Versión para pacientes |
Información revisada por expertos sobre el tratamiento de los tumores de estroma gastrointestinal. |
| pequeñas incisiones | 0.627953 |
| siguientes procedimientos | 0.660138 |
| cuidado médico | 0.818499 |
| tubo gi.ampliar | 0.664881 |
| siguientes aspectos | 0.645973 |
| Neurofibromatosis tipo | 0.638907 |
| siguientes sÃndromes | 0.651683 |
| rayos x | 0.707199 |
| enlace drugs approved | 0.645052 |
| escáner tep | 0.637347 |
| ondas sonoras | 0.640024 |
| National Cancer Institute | 0.620652 |
| causarán signos | 0.637878 |
|
| siguientes riesgos | 0.61572 |
| Instituto Nacional | 0.681879 |
| PDQ Tratamiento | 0.652674 |
| siguientes problemas | 0.648983 |
| tubo gi | 0.979564 |
| Physician Data Query | 0.683259 |
| tumor mide | 0.671706 |
| PDQ Cánceres | 0.69873 |
| siguientes enlaces | 0.62151 |
| siguientes órganos | 0.656962 |
| siguientes pruebas | 0.650191 |
| Gastrointestinal Stromal Tumors | 0.704979 |
|
CLICK HERE |
| 3428 |
National Cancer Institute |
Html |
es |
Terapia fotodinámica para el cáncer |
Hoja informativa que explica en qué consiste la terapia fotodinámica, cómo se administra y las indicaciones y los efectos secundarios del tratamiento. |
| Molecular Biology | 0.32441 |
| photodynamic therapy | 0.633479 |
| photodynamic treatment | 0.328771 |
| Henderson BW | 0.324256 |
| Drug Administration | 0.328891 |
| causa efectos | 0.325407 |
| sustancia fotosensiblizadora | 0.344827 |
| Fukumura D | 0.324644 |
| Dongen GA | 0.325062 |
| Jain RK | 0.326105 |
| multidrug-resistant tumors | 0.324624 |
| porfÃmero sódico | 0.914711 |
| Snow GB | 0.3246 |
| luz solar | 0.46733 |
| sustancia fotosensibilizadora | 0.526993 |
|
| vÃas respiratorias | 0.328731 |
| Biomedical Science | 0.324903 |
| Dougherty TJ | 0.324729 |
| determinados tipos | 0.331782 |
| Reviews Cancer | 0.32893 |
| cabo estudios | 0.366968 |
| cuello uterino | 0.325997 |
| Capella LS | 0.324402 |
| PubMed Abstract | 0.802286 |
| medicamento fotosensibilizador | 0.406789 |
| Cancer Institute | 0.326562 |
| Pottier RH | 0.324615 |
| Visser GW | 0.325175 |
| Goyan RL | 0.324518 |
|
CLICK HERE |
| 3460 |
National Cancer Institute |
Html |
es |
Coenzima Q10 (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso de la coenzima Q10 como tratamiento para las personas con cáncer. |
| Natl Acad Sci | 0.506232 |
| animal models | 0.503048 |
| Lockwood K | 0.522246 |
| Friend leukemia virus | 0.50335 |
| Mol Aspects Med | 0.525442 |
| Prog Drug Res | 0.505422 |
| Exp Clin Res | 0.507107 |
| Ernster L | 0.506157 |
| Clin Investig | 0.504327 |
| vitamina q10 | 0.508703 |
| vitamin q10 | 0.549224 |
| Health Syst Pharm | 0.503499 |
| Chem Pathol Pharmacol | 0.515808 |
| Bliznakov EG | 0.512562 |
| Hanioka T | 0.504235 |
| coenzyme q10 | 0.845306 |
| with vitamin q10 | 0.522905 |
| reticuloendothelial system upon | 0.50329 |
| Res Commun Chem | 0.525595 |
| coenzima q10 | 0.990386 |
| Nylander M | 0.503126 |
| system upon stimulation | 0.503357 |
| coenzima q.10 | 0.50372 |
| Coenzyme Q10 administration | 0.515239 |
| patients with | 0.52239 |
|
| Clinical Aspects | 0.506167 |
| Folkers K | 0.720923 |
| patients treated with | 0.503528 |
| Osterborg A | 0.503093 |
| coenzima q10 resumen | 0.509859 |
| Commun Chem Pathol | 0.52121 |
| Moesgaard S | 0.509545 |
| Biophys Res Commun | 0.66246 |
| Chemother Rep | 0.503476 |
| Nordenbrand K | 0.502764 |
| Proc Natl Acad | 0.506461 |
| Apparent partial remission | 0.503092 |
| Biochem Biophys Res | 0.653978 |
| with nutritional antioxidants | 0.504649 |
| coenzima q10 ayuda | 0.51293 |
| Drugs Exp Clin | 0.50459 |
| conzima q10 | 0.506965 |
| Overvad K | 0.504381 |
| Clin Nutr | 0.503026 |
| serious deficiency | 0.503488 |
| coenzyme q10 concentrations | 0.523415 |
| radicales libres | 0.504036 |
| essential fatty acids | 0.503269 |
| Yamashita S | 0.503124 |
|
CLICK HERE |
| 3769 |
National Cancer Institute |
Html |
es |
Medicina de precisión en el tratamiento del cáncer |
Información sobre el papel que tiene la medicina de precisión en el tratamiento del cáncer. |
| precisión para tratamiento | 0.796037 |
| máquina llamada secuenciador | 0.682468 |
| cuáles cambios | 0.881741 |
| cuáles tratamientos funcionarán | 0.880419 |
| que los pacientes | 0.633734 |
|
| campo de investigación | 0.604701 |
| seguro médico | 0.550546 |
| cáncer el cambio | 0.9829 |
| responda el tumor | 0.621072 |
| a cuáles tratamientos | 0.724195 |
|
CLICK HERE |
| 16842 |
National Cancer Institute |
Html |
en |
Johns Hopkins University — Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research |
The focus of the Johns Hopkins University Cancer Nanotechnology Training Center is presented here. |
| predoctoral fellows | 0.736483 |
| cancer nanobiotechnology | 0.632531 |
| optimal treatment | 0.545276 |
| Johns Hopkins University | 0.729715 |
| journal club | 0.539106 |
| novel cancer diagnostics | 0.713403 |
| program fosters | 0.562779 |
| steady state number | 0.670018 |
| epigenetic markers | 0.560601 |
| tumor boards | 0.538166 |
| NTCR program | 0.576419 |
| new frontier | 0.564875 |
| individual patient | 0.643505 |
| engineering/physics discipline | 0.563571 |
| physical sciences-oncology center | 0.676488 |
| lab course | 0.540911 |
| new modalities | 0.563 |
| cellular / cancer | 0.59221 |
| Johns Hopkins Institute | 0.669855 |
| dedicated annual symposium | 0.651728 |
| experimental facilities | 0.538368 |
| Vivo Cellular | 0.548936 |
| Molecular Imaging Center | 0.688968 |
| black-box input-output techniques | 0.710638 |
|
| scientific exploration | 0.554225 |
| clinical resources | 0.5443 |
| human diseases | 0.555299 |
| cancer cell functions | 0.720912 |
| clinical conferences | 0.540551 |
| high-throughput diagnostic tools | 0.682779 |
| non-viral delivery systems | 0.686087 |
| unique educational resources | 0.657197 |
| postdoctoral fellows | 0.715577 |
| Principal Investigator | 0.564913 |
| therapeutic tools | 0.551025 |
| Pancreatic Cancer Center | 0.731915 |
| Ludwick Center | 0.581555 |
| NTCR trainees | 0.59515 |
| cancer nanotechnology excellence | 0.742492 |
| outstanding trainees | 0.578764 |
| disease phenotype | 0.55677 |
| Comprehensive Cancer Center | 0.727928 |
| Cancer Genetics | 0.585039 |
| NTCR fellows | 0.742981 |
| engineer novel drug/antibody/siRNA | 0.668859 |
| human cancers | 0.551276 |
| core courses | 0.541397 |
| Training Focus | 0.565904 |
|
CLICK HERE |